What is the enterprise value (EV) for Compugen Ltd. (CGEN)?

The enterprise value (EV) for CGEN stock is $127.82M.

Compugen (CGEN) Enterprise Value: History & Chart

Compare

Compugen Ltd.(CGEN)

Biotechnology · Holon, TA

$2.310.00 (0.00%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

Compare

About Compugen Ltd.

Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors. COM902, a therapeutic antibody designed to target TIGIT, which is also in Phase I clinical trials as a monotherapy for advanced malignancies. Bapotulimab, an antibody targeting ILDR2, presently in Phase I clinical development for solid tumor indications. AZD2936, an innovative bispecific antibody targeting both TIGIT and PD-1, advancing through Phase I/II clinical studies for patients with advanced or metastatic non-small cell lung cancer. Additionally, Compugen maintains earlier-stage immuno-oncology programs, with a particular emphasis on myeloid targets. To further its research and development, Compugen actively fosters strategic alliances. It has a collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics that modulate immune checkpoint regulators. Another key partnership is with Bristol-Myers Squibb, aimed at evaluating the safety and tolerability of COM701 when administered alongside Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. The company also collaborates with Johns Hopkins School of Medicine to investigate novel T cell and myeloid checkpoint targets, and has a distinct research collaboration with Johns Hopkins University specifically dedicated to myeloid science. Furthermore, Compugen holds a licensing agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products.

Holon, TA

75 employees

cgen.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Eran Ophir

View full financials

NAME	MARKET CAP	ENTERPRISE VALUE (EV)
Compugen Ltd. (CGEN)	$218.42M	$127.82M
Alector, Inc. (ALEC)vs ›	$220.94M	$193.78M
Electra Therapeutics Inc. (ETRA)vs ›	$206.61M	N/A
AN2 Therapeutics, Inc. (ANTX)vs ›	$202.05M	$157.73M
Biodesix, Inc. (BDSX)vs ›	$236.56M	$278.36M
BioAge Labs Inc. (BIOA)vs ›	$239.45M	$168.32M
High Tide Inc. (HITI)vs ›	$239.89M	$294.34M
Eledon Pharmaceuticals, Inc. (ELDN)vs ›	$192.97M	$186.63M
Akebia Therapeutics, Inc. (AKBA)vs ›	$244.25M	$142.66M
Galectin Therapeutics Inc. (GALT)vs ›	$245.65M	$370.08M

NAME

MARKET CAP

ENTERPRISE VALUE (EV)

Compugen Ltd. (CGEN)

$218.42M

$127.82M

Alector, Inc. (ALEC)vs ›

$220.94M

$193.78M

Electra Therapeutics Inc. (ETRA)vs ›

$206.61M

N/A